Possible diabetes cure being tested on small number of patients
NEW YORK (AP) -- Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could cure the life-threatening hormonal disorder. They've already begun testing it in a small number of diabetic patients -- a first.